Market Overview

Genprex Reports Q3 R&D Expense ~$489K, Says 'increase in the current year period was driven entirely by increased R&D and commercialization activities associated with the development of our drug candidate and the progression of our Phase I/II trial...'

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Posted-In: News FDA

 

Related Articles (GNPX)

US And China Face Last Chance To Avoid Jan. 1 Tariff Hikes, But Don't Get Your Hopes Up

The Daily Biotech Pulse: Denali's Positive Results, Novartis' Substance Abuse Therapy Launch, Medtronic Earnings